Business
Vedanta Presents Data on Immuno-Oncology Candidate
Vedanta Presents Data on Immuno-Oncology Candidate.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 4148G PureTech Health PLC 06 November 2018 \n\n6 November 2018\n \nPureTech Health plc\n \nPureTech Health's Vedanta Biosciences to Present Preclinical Data on Microbiome-Derived Immuno-Oncology Candidate at Major Conference\n \nPureTech Health plc (LSE: PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis, is pleased to note that Vedanta Biosciences today announced data for VE800, its orally-administered, live biotherapeutic product candidate in immuno-oncology. The preclinical data showed that VE800 induced a systemic, anti-tumour immune response both as a monotherapy and in combination with checkpoint inhibitors. Additionally, the results describe a mechanism of action for VE800 as the robust interferon-gamma producing CD8+ (cytotoxic) T cell response was elicited via activation of dendritic cells. The data will be presented at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting on 8 November. Vedanta Biosciences expects to initiate a clinical study of VE800 in mid-2019.\n \nBharatt Chowrira, JD, PhD, President and Chief of Business and Strategy at PureTech Health, said: \"The new data support the potential of VE800 as a unique approach to immuno-oncology - both as a monotherapy and to enhance the effects of checkpoint inhibitors. We look forward to the initiation of a clinical study next year and to the continued progress of Vedanta's pipeline.\"\n \nThe full text announcement from Vedanta Biosciences is as follows:\nVedanta Biosciences Announces Preclinical Data on Microbiome-Derived Immuno-Oncology Candidate\n \nVE800 shown to induce cytotoxic T cells and a systemic immune response both as a monotherapy and in combination with checkpoint inhibitors\n \nFirst detailed description of anti-tumour activity mediated by commensal bacteria that have been associated with clinical response to checkpoint inhibitors\n \nThese data to be presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting\n \nCAMBRIDGE, Mass., Nov. 6, 2018-Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced preclinical...